Subcutaneous Olanzapine for Hyperactive or Mixed Delirium
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the tolerability and safety of olanzapine
administered as a subcutaneous injection to hospitalized patients with hyperactive or mixed
delirium.